BRIEF published on 07/15/2025 at 09:05, 7 months 5 days ago AATec Medical et Northway Biotech forment un partenariat pour le développement de la production d'ATL-105 Partenariat ATL-105 Fabrication De Produits Biologiques Maladies Pulmonaires Thérapie Respiratoire
BRIEF published on 07/15/2025 at 09:05, 7 months 5 days ago AATec Medical and Northway Biotech Form Partnership for ATL-105 Production Development Partnership ATL-105 Biologics Manufacturing Lung Diseases Respiratory Therapy
PRESS RELEASE published on 07/15/2025 at 09:00, 7 months 5 days ago AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Diseases AATec Medical and Northway Biotech announce partnership to develop industrial production process for ATL-105 targeting lung diseases Partnership AATec Medical ATL-105 Lung Diseases Northway Biotech
BRIEF published on 04/15/2025 at 11:09, 10 months 5 days ago AATec Medical obtient 4 millions d'euros pour le développement de médicaments respiratoires Biotechnologie Financement Essais Cliniques Développement De Médicaments Maladies Respiratoires
BRIEF published on 04/15/2025 at 11:09, 10 months 5 days ago AATec Medical Secures EUR 4 Million for Respiratory Drug Development Biotechnology Funding Clinical Trials Drug Development Respiratory Diseases
PRESS RELEASE published on 04/15/2025 at 11:04, 10 months 5 days ago AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development AATec Medical secures EUR 4 million funding to advance lead respiratory drug candidate, ATL-105, for clinical development to treat non-CF bronchiectasis by 2026 Clinical Development AATec Medical Non-CF Bronchiectasis EUR 4 Million Respiratory Drug Candidate
BRIEF published on 09/18/2024 at 10:05, 1 year 5 months ago AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board Scientific Advisory Board AATec Medical James Chalmers Bronchiectasis Recombinant AAT
BRIEF published on 09/18/2024 at 10:05, 1 year 5 months ago AATec Medical accueille le professeur James Chalmers au sein de son conseil consultatif scientifique AATec Medical Conseil Consultatif Scientifique James Chalmers Bronchectasie AAT Recombinante
PRESS RELEASE published on 09/18/2024 at 10:00, 1 year 5 months ago AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board AATec Medical welcomes Professor James Chalmers, a renowned expert in respiratory medicine, to its Scientific Advisory Board to advance product development in non-CF bronchiectasis Scientific Advisory Board AATec Medical Professor James Chalmers Respiratory Medicine Non-CF Bronchiectasis
BRIEF published on 07/24/2024 at 10:05, 1 year 6 months ago AATec Medical Makes Significant Strides in First Year of Operations Biotechnology Clinical Trials AATec Medical ATL-105 Inflammatory Lung Diseases
Published on 02/20/2026 at 18:30, 16 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 3 hours 1 minute ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 4 hours 16 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 4 hours 38 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 4 hours 46 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 10 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 15 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 46 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 46 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 09:28, 9 hours 18 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 9 hours 18 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
